Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.31 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.31 |
| ▸ | PDE1A | P54750 | 1/20 | 0.31 |
| ▸ | SPR | P35270 | 1/20 | 0.31 |
| ▸ | FPR1 | P21462 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | MAP3K12 | Q12852 | 6/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24006951 | 0.92 | PDE4D (0.36) | CNR2PDE1BPDE1CPDE1APDE4D | |
| SCHEMBL26937943 | 0.84 | TMEM97 (0.32) | CNR2PDE4D | |
| SCHEMBL24813965 | 0.81 | CNR2 (0.37) | CNR2SRCSPRFPR1MAP3K12 | |
| SCHEMBL24816290 | 0.81 | CNR2 (0.37) | CNR2SRCPDE1BPDE1CPDE1A | |
| SCHEMBL24815073 | 0.80 | CNR2 (0.36) | CNR2SRCSPRFPR1MAP3K12 | |
| SCHEMBL24007026 | 0.80 | CNR2 (0.36) | CNR2SRCSPRFPR1MAP3K12 | |
| SCHEMBL24007277 | 0.80 | CNR2 (0.36) | CNR2SRCSPRFPR1MAP3K12 | |
| SCHEMBL24942330 | 0.80 | CNR2 (0.36) | CNR2SRCPDE1BPDE1CPDE1A | |
| SCHEMBL26013186 | 0.80 | CNR2 (0.39) | CNR2 | |
| SCHEMBL24815015 | 0.79 | CNR2 (0.36) | CNR2SRCSPRFPR1MAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | CNR2 3981/4885SRC 19/4885PDE1B 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.